163 related articles for article (PubMed ID: 21631550)
1. Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome.
Quigley EM
Aliment Pharmacol Ther; 2011 Jul; 34(1):100-1; author reply 101. PubMed ID: 21631550
[No Abstract] [Full Text] [Related]
2. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
Guglielmetti S; Mora D; Gschwender M; Popp K
Aliment Pharmacol Ther; 2011 May; 33(10):1123-32. PubMed ID: 21418261
[TBL] [Abstract][Full Text] [Related]
3. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
Andresen V; Gschossmann J; Layer P
Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):658-666. PubMed ID: 32277872
[TBL] [Abstract][Full Text] [Related]
4. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
Camilleri M
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
[TBL] [Abstract][Full Text] [Related]
5. The use of probiotics in the treatment of irritable bowel syndrome.
Gaby AR
Altern Ther Health Med; 2006; 12(1):17; author reply 17. PubMed ID: 16454141
[No Abstract] [Full Text] [Related]
6. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
[TBL] [Abstract][Full Text] [Related]
7. Failure to define what constitutes a patient responder is a problem in the interpretation of the probiotic clinical trial evaluating the use of Bifidobacterium in irritable bowel syndrome.
van Zanten SV
Gastroenterology; 2005 Aug; 129(2):772; author 772-3. PubMed ID: 16083745
[No Abstract] [Full Text] [Related]
8. The use of probiotics in the treatment of irritable bowel syndrome: two case reports.
Faber S; Rigden S; Lukaczer D
Altern Ther Health Med; 2005; 11(4):60-2. PubMed ID: 16053123
[No Abstract] [Full Text] [Related]
9. Probiotics and functional gastrointestinal disorders in children.
Vandenplas Y; Benninga M
J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S107-9. PubMed ID: 19300120
[TBL] [Abstract][Full Text] [Related]
10. [Irritable bowel syndrome. Reduction of symptoms, better quality of life].
MMW Fortschr Med; 2011 May; 153(19):52-3. PubMed ID: 21612101
[No Abstract] [Full Text] [Related]
11. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
Brenner DM; Chey WD
Rev Gastroenterol Disord; 2009; 9(1):7-15. PubMed ID: 19367213
[TBL] [Abstract][Full Text] [Related]
12. Review article: probiotics and prebiotics in irritable bowel syndrome.
Spiller R
Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.
Williams EA; Stimpson J; Wang D; Plummer S; Garaiova I; Barker ME; Corfe BM
Aliment Pharmacol Ther; 2009 Jan; 29(1):97-103. PubMed ID: 18785988
[TBL] [Abstract][Full Text] [Related]
14. Metabonomic understanding of probiotic effects in humans with irritable bowel syndrome.
Hong YS; Hong KS; Park MH; Ahn YT; Lee JH; Huh CS; Lee J; Kim IK; Hwang GS; Kim JS
J Clin Gastroenterol; 2011; 45(5):415-25. PubMed ID: 21494186
[TBL] [Abstract][Full Text] [Related]
15. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms.
Dughera L; Elia C; Navino M; Cisarò F;
Acta Biomed; 2007 Aug; 78(2):111-6. PubMed ID: 17933278
[TBL] [Abstract][Full Text] [Related]
16. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome.
Kajander K; Krogius-Kurikka L; Rinttilä T; Karjalainen H; Palva A; Korpela R
Aliment Pharmacol Ther; 2007 Aug; 26(3):463-73. PubMed ID: 17635381
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy of activia tvorozhnaya in patients with the irritated bowels syndrome with the prevalence of constipations].
Parfenov AI; Ruchkina IN; Silvestrova SIu
Eksp Klin Gastroenterol; 2005; (3):37-42. PubMed ID: 16255551
[No Abstract] [Full Text] [Related]
18. Improved adhesive properties of recombinant bifidobacteria expressing the Bifidobacterium bifidum-specific lipoprotein BopA.
Gleinser M; Grimm V; Zhurina D; Yuan J; Riedel CU
Microb Cell Fact; 2012 Jun; 11():80. PubMed ID: 22694891
[TBL] [Abstract][Full Text] [Related]
19. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study.
Colecchia A; Vestito A; La Rocca A; Pasqui F; Nikiforaki A; Festi D;
Minerva Gastroenterol Dietol; 2006 Dec; 52(4):349-58. PubMed ID: 17108864
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of adhesion properties and antibacterial activities of the infant gut commensal Bifidobacterium bifidum PRL2010.
Serafini F; Strati F; Ruas-Madiedo P; Turroni F; Foroni E; Duranti S; Milano F; Perotti A; Viappiani A; Guglielmetti S; Buschini A; Margolles A; van Sinderen D; Ventura M
Anaerobe; 2013 Jun; 21():9-17. PubMed ID: 23523946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
